FSD Pharma Says Arbitration Panel Finds That Nasdaq-listed Syneos Health "Failed to Use Commercially Reasonable Efforts in Conducting Its Trial for FSD 201"
FSD Pharma Says Arbitration Panel Finds That Nasdaq-listed Syneos Health "Failed to Use Commercially Reasonable Efforts in Conducting Its Trial for FSD 201"
fsd pharma表示，仲裁小组发现在为fsd 201进行试验时，纳斯达克上市的Syneos Health未尽商业合理努力。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间